Navigation Links
SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS
Date:9/1/2010

CALGARY, Sept. 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS) today announced that the United States Patent and Trade Mark Office has granted the Company U.S. patent 7,786,352 entitled "Methods for the Production of Apolipoproteins in Transgenic Plants". The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into mature plants which produce seeds that express apolipoprotein. This patent is key to successfully commercializing plant made and seed expressed Apo AI(Milano).

The intent of the Company's global patent strategy is to own exclusive rights to transgenic production of biosimilar drugs and novel drug candidates like Apo AI(Milano) in select plant and plant-seed lines and to be able to make such drugs in a scalable and affordable manner. In doing so, the Company believes it is rapidly becoming a highly attractive partner to large pharma partners looking to enter these markets with a differentiated and patent protected manufacturing cost structure.

"The issuance of this patent and the continuing success of our Apo AI(Milano) development strengthens the program as we advance through the partnership process with interested parties. This newly granted patent significantly enhances the value of our development and commercialization program for Apo AI(Milano), our next-generation cardiovascular drug candidate with blockbuster potential," said James Szarko, President and CEO of SemBioSys. "Apo AI(Milano) has the potential to address large unmet medical needs as an acute treatment for atherosclerosis or arterial blockage caused by plaque build-up on arterial walls, which leads to stroke and heart attacks. Our plant-seed based expression system for the production of Apo, biosimilar drugs and potentially other novel pharmaceutical drug candidates is a truly disr
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. SemBioSys begins phase I/II trial of insulin produced in plant seeds
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. SemBioSys announces senior management changes
5. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
6. SemBioSys provides update on insulin program
7. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
8. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
9. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
10. SemBioSys provides an update on Botaneco
11. SemBioSys announces third quarter 2009 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
(Date:4/30/2015)... MA & Budapest, Hungary (PRWEB) April 30, 2015 ... only web-based electronic lab notebook with integrated protocols ... in providing chemistry software solutions and consulting services ... led to the development of Labguru’s newest feature: ... set of deep domain features for biologists, bio-chemists, ...
(Date:4/30/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a ... biosimilar therapeutics including high value and difficult to ... previously announced underwritten public offering of 6,750,000 shares ... price of $15.50 per share. This includes the ... option to purchase up to 750,000 additional shares ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... 6 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced ... any and all of its outstanding 3.0% Convertible,Notes due ... Time on,October 4, 2007, unless extended. The tender offer, ... the related letter of transmittal, is not,subject to the ...
... and ST. LOUIS, Sept. 6 Resource ... (GPO) serving St. Louis-,based Sisters of Mercy ... Elekta,enabling members to begin purchasing Elekta,s innovative ... ) Under the agreement, Mercy will ...
... BARCELONA, Spain, Sept. 6 Elekta, a ... solutions, will showcase,the latest advances in radiotherapy, ... European Society of Therapeutic Radiation,Oncologists (ESTRO) 2007 ... 2,000 physicists, radiotherapists, oncologists and other health ...
Cached Biology Technology:NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 3NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 4Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 3
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... has been a focal point of recent climate change research ... than the larger Antarctic ice sheet. Yet while the southern ... clear how much this is contributing to rising sea levels, ... research was defined at a recent workshop organised by the ...
... overlooked and undervalued protein, sarcospan, just got its ... show that adding it to muscle cells might ... In Duchenne muscular dystrophy (DMD), the mutated dystrophin ... glycoprotein complex. And without this anchoring, muscle cells ...
... day be mended using a novel scaffold developed by MIT ... heart cells or stem cells seeded onto such a scaffold ... be used to treat congenital heart defects, or aid the ... scaffold would be gradually absorbed into the body, leaving behind ...
Cached Biology News:What is really happening to the Greenland icecap? 2MIT: Mending broken hearts with tissue engineering 2
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
... Neural Stem Cell Expansion Kit - Monolayer is ... NSC expansion as a monolayer in a serum-free ... Plus Media Supplement, which has been optimized for ... al . (1996) Genes & Development 10 ...
... DNA Polymerase I from E. ... polymerase. The enzyme also contains ... The 5'?3' exonuclease activity enables ... and gaps in the DNA ...
Biology Products: